VC
CBAY

Vivo Capital’s Cymabay Therapeutics CBAY Stock Holding History

Vivo Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-585,394
Closed -$3.36M – 69
2020
Q4 		$3.36M Sell
585,394
-1,503,962
-72% -$11.4M 0.15% 52
2020
Q3 		$15.1M Hold
2,089,356
– – 0.87% 33
2020
Q2 		$7.29M Buy
2,089,356
+1,011,889
+94% +$2.92M 0.52% 39
2020
Q1 		$1.59M Buy
+1,077,467
New +$1.81M 0.14% 49
2019
Q3 		– Sell
-2,154,934
Closed -$15.4M – 33
2019
Q2 		$15.4M Buy
2,154,934
+98,934
+5% +$1.12M 1.45% 20
2019
Q1 		$27.3M Buy
2,056,000
+1,150,000
+127% +$12.2M 2.72% 12
2018
Q4 		$7.13M Hold
906,000
– – 0.91% 29
2018
Q3 		$10M Hold
906,000
– – 1.01% 25
2018
Q2 		$12.2M Buy
906,000
+106,000
+13% +$1.33M 1.57% 18
2018
Q1 		$10.4M Buy
+800,000
New +$9.94M 1.47% 17

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vivo Capital's CBAY Position: Q1 2021 in Review

Vivo Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2021, closing a stake of 585,394 shares — an estimated $3.36M sold.

Vivo Capital first reported a position in CBAY in Q1 2018 and held it in 10 quarters. The position peaked at $27.3M in Q1 2019. 130 funds tracked by Wall St. Rank hold CBAY as of Q1 2021.

  • Vivo Capital reported no remaining Cymabay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Vivo Capital sold 585,394 Cymabay Therapeutics shares in Q1 2021, an estimated $3.36M.
  • Vivo Capital first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 10 quarters.
  • Vivo Capital's Cymabay Therapeutics position peaked at $27.3M in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2021.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.